Flow cytometry evaluation of acute myeloid leukemia minimal residual disease based on an understanding of the normal maturation patterns in the blast compartments
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae187 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Mikhail Roshal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematopathology, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, US. Hauptthemen laut MEDLINE: Flow Cytometry, Leukemia, Myeloid, Acute, Neoplasm, Residual. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben.
Abstract (Originalsprache)
Objective
Detection of minimal/measurable disease (MRD) in acute myeloid leukemia (AML) is critical for both clinical decision-making and prognostication, yet remains a challenge. Flow cytometry is a well-established method for MRD detection. Flow cytometric (FC) evaluation of MRD must consider a complex maturational pattern of normal hematopoietic development to separate normal from abnormal progenitors. Here, we offer an example of an interpretive approach based on a thorough understanding of stage- and lineage-specific hematopoietic maturation.
Methods
We provide a comprehensive overview of blast maturation from early precursors (hematopoietic stem cells) to committed late-stage unilineage progenitors and commonly observed stage-specific abnormalities based on cases we have encountered in practice. We emphasize the importance of stage-specific comparisons for accurate MRD detection by flow cytometry.
Results
The AML blasts almost invariably show abnormal phenotypes, and the phenotypes may evolve upon therapy. The detected phenotypes are necessarily confined to the target antigens included in the panel. It is therefore critical to evaluate a range of antigens to establish a specific stage/state of lineage commitment and detect potential common abnormalities. Moreover, enough cells must be acquired to allow for the detection of MRD at desired levels. Significant technical and analytical validation is critical.
Conclusions
Flow cytometry offers a powerful single-cell-based platform for MRD detection in AML, and the results have been proven critical for disease management. Leukemia-associated phenotype-informed difference from the normal approach presented in this review presents an analytical framework for sensitive and accurate MRD detection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematopathology, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, US.
Zitieren
APA
Roshal, M., & Gao, Q. (2025). Flow cytometry evaluation of acute myeloid leukemia minimal residual disease based on an understanding of the normal maturation patterns in the blast compartments. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae187
Vancouver
Roshal M, Gao Q. Flow cytometry evaluation of acute myeloid leukemia minimal residual disease based on an understanding of the normal maturation patterns in the blast compartments. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae187
BibTeX
@article{Roshal2025,
author = {Roshal, Mikhail and Gao, Qi},
title = {Flow cytometry evaluation of acute myeloid leukemia minimal residual disease based on an understanding of the normal maturation patterns in the blast compartments},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae187}
}
EUVIMED